Engineering Novel Antibody Oligonucleotide Conjugates (AOC™)

Avidity Biosciences is a privately held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC^™), which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease. Avidity is advancing a pipeline of therapeutic programs focused on rare muscle disorders and other serious diseases.